DAPT in ACS vs CSA
In acute coronary syndrome (ACS), dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor must be continued for at least 12 months, whereas in chronic stable angina (CSA)/stable ischemic heart disease (SIHD), DAPT is only indicated for 6 months after drug-eluting stent (DES) implantation or 1 month after bare metal stent (BMS), with no benefit for DAPT in stable patients without prior stenting, recent ACS, or CABG. 1, 2, 1
Key Differences in DAPT Strategy
Acute Coronary Syndrome (ACS)
The fundamental distinction is that ACS represents an acute thrombotic event requiring aggressive antiplatelet therapy to prevent recurrent ischemic complications:
- Mandatory 12-month DAPT duration regardless of stent type (BMS or DES) or whether revascularization was performed 1, 2, 1
- Preferred P2Y12 inhibitors: Ticagrelor or prasugrel over clopidogrel (Class IIa recommendation) 2, 3
- Ticagrelor is reasonable for all ACS patients
- Prasugrel is reasonable for patients without prior stroke/TIA and not at high bleeding risk
- Aspirin dose: 81 mg daily (range 75-100 mg) 1, 2
Extension beyond 12 months may be reasonable (Class IIb) in patients who:
- Have tolerated DAPT without bleeding complications
- Are not at high bleeding risk
- Do not have contraindications like coagulopathy or oral anticoagulant use 1, 2
Early discontinuation at 6 months may be reasonable (Class IIb) only in patients who develop high bleeding risk or significant overt bleeding 2
Chronic Stable Angina/SIHD
The approach is fundamentally different because the thrombotic risk is lower and bleeding risk becomes more prominent over time:
After PCI with stenting:
- DES: Minimum 6 months of DAPT with clopidogrel (Class I) 1, 2
- BMS: Minimum 1 month of DAPT with clopidogrel (Class I) 1, 2
- Clopidogrel is the only studied P2Y12 inhibitor in this population 1
High bleeding risk patients may discontinue after 3 months with DES (Class IIb) 1, 2
Extension beyond standard duration (>6 months for DES, >1 month for BMS) may be reasonable (Class IIb) only in highly selected patients who have tolerated DAPT without complications 1, 2
No prior stenting/ACS/recent CABG: DAPT provides no benefit (Class III: No Benefit) 1, 2
Clinical Algorithm for Decision-Making
Step 1: Classify the Clinical Presentation
- ACS (STEMI, NSTEMI, unstable angina) → 12-month default
- SIHD/CSA → Duration based on stent type and bleeding risk
Step 2: For ACS Patients
- Start aspirin 81 mg + ticagrelor or prasugrel (or clopidogrel if contraindications exist)
- Continue for minimum 12 months
- At 12 months, reassess:
- Low bleeding risk + no complications → Consider extension (Class IIb)
- High bleeding risk or bleeding event → Discontinue P2Y12 inhibitor, continue aspirin
Step 3: For SIHD/CSA Patients Post-PCI
DES implanted:
- Standard risk: 6 months DAPT with clopidogrel
- High bleeding risk: Consider 3 months (Class IIb)
BMS implanted:
- Minimum 1 month DAPT with clopidogrel
After completing minimum duration:
- Transition to aspirin monotherapy
- Extension only if tolerated well and patient preference (Class IIb)
Step 4: For SIHD Without Recent Intervention
- No DAPT indicated - aspirin monotherapy only 1
Critical Pitfalls to Avoid
Do not treat stable CAD patients like ACS patients: The 12-month DAPT recommendation is specific to ACS and does not apply to elective PCI in stable disease 1. Overtreatment increases bleeding risk without ischemic benefit.
Do not use prasugrel or ticagrelor routinely in SIHD: These agents are only studied and recommended for ACS; clopidogrel is the evidence-based choice for stable disease 1, 3.
Recognize the transition period: Patients with ACS >1 year prior who remain event-free are considered to have transitioned to SIHD 1, 2. At this point, the rationale for continued DAPT diminishes significantly.
Bleeding risk assessment is mandatory: High bleeding risk features include prior bleeding on DAPT, coagulopathy, oral anticoagulant use, age ≥75 years, chronic kidney disease, and thrombocytopenia 1, 4. These patients require abbreviated DAPT strategies.
Evidence Strength and Nuances
The 2016 ACC/AHA guidelines 1, 2, 1 and 2017 ESC guidelines 3 are concordant on these core principles. The 2025 ACC/AHA ACS update 5 and 2024 ESC CCS guidelines 6 reaffirm these recommendations with additional emphasis on bleeding risk mitigation strategies.
The most recent high-quality evidence supports that in stable CAD, shorter DAPT (3-6 months) is non-inferior to 12 months for major adverse cardiovascular events while reducing bleeding 4. Conversely, in ACS, the 12-month duration remains evidence-based from landmark trials (CURE, PLATO, TRITON-TIMI 38) 2, 3.
The 2018 guideline comparison 4 emphasizes the paradigm shift toward individualized, shorter default DAPT in stable disease, contrasting sharply with the fixed 12-month requirement in ACS.